Dosage guide · 10 mg vial

Survodutide Dosage Protocol

BI 456906 · investigational GLP-1/glucagon dual agonist

The published phase 2 schedule starts at 0.3 mg once weekly for 2 weeks, then rises in two-week steps to 6 mg from week 23. With 1 mL of bacteriostatic water, a 10 mg vial is 10 mg/mL, so the 0.3 mg start amount is 3 units on a U-100 syringe. The protocol used a slower escalation to help manage gastrointestinal effects.

How oftenOnce weekly

Starting dose0.3 mg

Start = units3 units

Mix1 mL BAC water

Reviewed 25 Oct 2026 · Education only, not medical advice

Survodutide 10 mg vial

Not currently stocked by Peak Peptides Australia

No product photo — this strength isn't stocked by Peak

Dosage chart How to mix Supplies Calculator About Survodutide References

01 · DOSAGE CHART

Survodutide dosage chart

Published gradual weekly steps · 10 mg vial + 1 mL BAC water

BAC water added

Concentration10 mg/mL

1 unit (U-100)100 mcg= 0.01 mL

How oftenOnce weeklySubcutaneous injection

No supplier mix is available because Peak does not stock it; 1 mL keeps the published 0.3–6 mg steps between 3 and 60 U-100 units.

Survodutide dosage chart for a 10 mg vial mixed with 1 mL of bacteriostatic water
Week	Weekly dose	Syringe units
Weeks 1–2Start	0.3 mg	3 units0.03 mL
Weeks 3–4	0.6 mg	6 units0.06 mL
Weeks 5–6	0.9 mg	9 units0.09 mL
Weeks 7–8	1.2 mg	12 units0.12 mL
Weeks 9–10	1.8 mg	18 units0.18 mL
Weeks 11–12	2.4 mg	24 units0.24 mL
Weeks 13–14	3 mg	30 units0.3 mL
Weeks 15–16	3.6 mg	36 units0.36 mL
Weeks 17–18	4.2 mg	42 units0.42 mL
Weeks 19–20	4.8 mg	48 units0.48 mL
Weeks 21–22	5.4 mg	54 units0.54 mL
Week 23 onwardsMaintenance	6 mg	60 units0.6 mL

Once weekly · same day each week · subcutaneous injection

This is the published 6 mg phase 2 escalation: each step was given once weekly for 2 weeks.

The trial protocol allowed dose adjustment for adverse effects; do not treat this research schedule as individual medical advice.

Published clinical-trial escalation for an investigational medicine that is not approved for use. Education only, not medical advice. Dose amounts adapted from BI 456906 phase 2 MASH and fibrosis clinical trial protocol (Boehringer Ingelheim via ClinicalTrials.gov, NCT04771273); units are recalculated for the vial and mix selected above.

02 · HOW TO MIX

Mixing a 10 mg vial with 1 mL of BAC water

Using a 1 mL (100-unit) insulin syringe, one full draw of bacteriostatic water gives 10 mg/mL.

1
Add the water slowly
Wipe both rubber stoppers with an alcohol swab and let them dry. Draw 1 mL of bacteriostatic water and let it run slowly down the inside of the vial wall — not straight onto the powder.
2
Swirl gently
Swirl or roll the vial gently until the powder has dissolved. Give it a few minutes to settle if needed.
3
Don't shake it
Shaking can damage the peptide and cause foaming. Gentle swirling only.
4
Check it's fully clear
Only use it once it is fully clear with no particles. Label the vial with the date and 10 mg/mL, then store it in the fridge at 2–8 °C.

Full illustrated reconstitution guide

03 · SUPPLIES NEEDED

What you'll need

Counts follow the dosage chart above at the highest amount in each step, using a 10 mg vial mixed with 1 mL.

Length of protocol

2Survodutide 10 mg vials14.4 mg needed in total

141 mL insulin syringesU-100, 27–31G · one per draw + one per vial mixed

1BAC water 10 mL bottle2 mL used for mixing

28Alcohol swabsSkin + stopper, every time

Plus an approved sharps container. Syringes and swabs are sold by Australian pharmacies — Peak Peptides and Pure Performance supply the bacteriostatic water.

Peak Peptides Australia Bacteriostatic water 10 mL

Bacteriostatic water 10 mLPeak Peptides Australia

Pure Performance Australia Bacteriostatic water 10 mL

Bacteriostatic water 10 mLPure Performance Australia

04 · CALCULATOR

Check a different amount

Enter your vial, water and dose to see the matching syringe units.

Concentration Calculator

Labelled Vial Amount (mg)

Verified Final Liquid Volume1 mL

Amount to Evaluate (not a recommendation)

Concentration

10.00 mg/mL

(10000 mcg/mL)

Calculated Liquid Volume

0.030 mL

Equivalent U-100 volume scale position

3markings (not biological IU)

Illustration of a U-100 volume scale, not preparation or injection guidance

05 · PROTOCOL DETAILS

About Survodutide

Protocol overview

Starting dose: 0.3 mg once weekly for weeks 1–2
How it increases: 0.3 mg, then 0.6 mg steps every 2 weeks to 6 mg from week 23
Frequency: Once weekly
When to take it: The protocol used a weekly subcutaneous schedule
Published treatment length: 48 weeks: up to 24 weeks escalating, then at least 24 weeks at maintenance
Default mix: 1 mL bacteriostatic water → 10 mg/mL

Storage

Before mixing: No supplier-specific storage instruction is available for this non-stocked reference vial; follow the validated vial label.
After mixing: Generic reconstituted-vial practice is refrigeration at 2–8 °C; follow the product label's use-by period.
Never: Never use a mixed vial that is cloudy or has particles in it.

How it works

Survodutide, also called BI 456906, is an investigational dual agonist of the glucagon receptor and GLP-1 receptor being developed by Boehringer Ingelheim for obesity and metabolic liver disease.

It activates two receptors involved in metabolic regulation. The developer describes GLP-1 activity as affecting appetite and fullness, while glucagon-receptor activity is thought to affect liver fat and energy metabolism; these proposed clinical effects remain under investigation.

Illustrated mechanism explainer

What the research shows

In the obesity phase 2 study, 386 participants received treatment for 46 weeks, including 20 weeks of escalation and 26 weeks of maintenance. Planned-treatment mean body-weight change at week 46 was −14.9% with 4.8 mg versus −2.8% with placebo.
That phase 2 obesity study tested 0.6, 2.4, 3.6 and 4.8 mg once weekly; adverse events occurred in 91% of survodutide recipients and gastrointestinal adverse events in 75%.
In the 48-week phase 2 MASH study of 293 participants, MASH improvement without worsening of fibrosis occurred in 47% at 2.4 mg, 62% at 4.8 mg and 43% at 6 mg, versus 14% with placebo.
In a 76-week phase 3 obesity study, mean body-weight change was −12.2% with 3.6 mg and −13.0% with 6 mg, compared with −5.4% with placebo. Survodutide remains investigational and has not been approved for use.
The TGA says the ARTG is the database of therapeutic goods approved for supply in Australia; no Survodutide or BI 456906 entry was located in the ARTG search checked for this guide.

Reported side effects

Gastrointestinal effects were the main reported adverse events. In phase 2 obesity, 232 of 309 survodutide recipients (75%) had gastrointestinal adverse events, compared with 32 of 77 placebo recipients (42%).
In the phase 2 MASH study, nausea occurred in 66% with survodutide versus 23% with placebo, diarrhoea in 49% versus 23%, and vomiting in 41% versus 4%.
The MASH study reported serious adverse events in 8% with survodutide and 7% with placebo. Human safety and long-term effects are still being evaluated.

Important notes

Survodutide is an investigational medicine and is not approved for use in Australia or the United States. It is not stocked by Peak Peptides Australia.
Prohibited in sport at all times: because it has no current governmental regulatory approval for human therapeutic use, it falls within WADA's S0 non-approved-substances class.
Published study material excluded people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, and people with a history of pancreatitis; this is not a substitute for clinical assessment.
The main phase 2 risks were nausea, diarrhoea and vomiting, particularly during dose escalation. Seek urgent clinical care for severe or persistent symptoms.
Never use a mixed vial that is cloudy or has particles in it.

Injection basics

Use a new sterile 1 mL (100-unit) U-100 insulin syringe, 27–31G, every time — never reuse or share.
Wipe the vial stopper and the skin with an alcohol swab and let both dry first.
Inject under the skin (subcutaneously) of the abdomen, thigh or upper arm, and rotate sites.
Put used syringes straight into an approved sharps container — the NDSS lists Australian disposal options.

Guidance: World Health Organization · National Diabetes Services Scheme (NDSS)

06 · QUICK ANSWERS

Survodutide questions

How many units is 300 mcg of Survodutide?

With the default 10 mg vial plus 1 mL (10 mg/mL), 300 mcg is 3 units, or 0.03 mL, on a U-100 syringe.

How many units is 6 mg of Survodutide?

With the default 10 mg/mL mix, 6 mg is 60 units, or 0.60 mL, on a U-100 syringe.

How much bacteriostatic water is used for a 10 mg Survodutide vial?

This reference guide uses 1 mL for a 10 mg/mL concentration. At that concentration, 1 mg is 10 units, or 0.10 mL, on a U-100 syringe.

How long does a 10 mg Survodutide vial last?

At 0.3 mg once weekly, 10 mg contains about 33.3 weekly doses. At 4.8 mg it contains about 2.1 weekly doses, and at 6 mg it contains about 1.7 weekly doses.

07 · SOURCES